Palvella Therapeutics Inc
PVLA103.370USD
-2.460-2.32%
收盤 12/26, 16:00（美東）報價延遲15分鐘
1.15B總市值
虧損本益比TTM
關於 Palvella Therapeutics Inc 公司
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Palvella Therapeutics Inc簡介
公司代碼PVLA
公司名稱Palvella Therapeutics Inc
上市日期Dec 18, 2014
CEOKaupinen (Wesley H)
員工數量14
證券類型Ordinary Share
年結日Dec 18
公司地址353 W. Lancaster Avenue
城市WAYNE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編19087
電話14842531461
網址https://palvellatx.com/
公司代碼PVLA
上市日期Dec 18, 2014
CEOKaupinen (Wesley H)
Palvella Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Todd C. Davis
Mr. Todd C. Davis
Independent Director
Independent Director
--
--
Mr. Tadd S. Wessel
Mr. Tadd S. Wessel
Independent Director
Independent Director
--
--
Dr. David W. Osborne, Ph.D.
Dr. David W. Osborne, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
--
--
Dr. Jeffrey (Jeff) Martini, Ph.D.
Dr. Jeffrey (Jeff) Martini, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. George M. Jenkins
Mr. George M. Jenkins
Independent Chairman of the Board
Independent Chairman of the Board
196.69K
+2.60%
Ms. Elaine J. Heron
Ms. Elaine J. Heron
Independent Director
Independent Director
51.29K
--
Mr. Christopher P. (Chris) Kiritsy
Mr. Christopher P. (Chris) Kiritsy
Independent Director
Independent Director
250.00
--
Ms. Kathleen Goin
Ms. Kathleen Goin
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Wesley H. (Wes) Kaupinen
Mr. Wesley H. (Wes) Kaupinen
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Mr. Matthew E. Korenberg
Mr. Matthew E. Korenberg
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Kaupinen (Wesley H.)
13.58%
BVF Partners L.P.
9.81%
Suvretta Capital Management, LLC
6.95%
Frazier Life Sciences Management, L.P.
6.10%
Integrated Finance Group
4.73%
其他
58.83%
持股股東
持股股東
佔比
Kaupinen (Wesley H.)
13.58%
BVF Partners L.P.
9.81%
Suvretta Capital Management, LLC
6.95%
Frazier Life Sciences Management, L.P.
6.10%
Integrated Finance Group
4.73%
其他
58.83%
股東類型
持股股東
佔比
Hedge Fund
29.48%
Investment Advisor/Hedge Fund
17.41%
Individual Investor
16.63%
Investment Advisor
13.20%
Private Equity
9.44%
Other Insider Investor
4.73%
Research Firm
2.39%
Venture Capital
1.87%
Bank and Trust
0.07%
其他
4.78%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
145
6.92M
62.61%
+1.10M
2025Q2
113
8.02M
72.53%
+1.47M
2025Q1
119
7.23M
65.51%
+2.66M
2024Q4
118
6.14M
54.71%
+5.00M
2024Q3
118
806.99K
64.03%
-218.37K
2024Q2
120
474.51K
38.85%
-479.71K
2024Q1
135
564.53K
48.12%
-430.81K
2023Q4
149
574.40K
48.95%
-409.12K
2023Q3
161
703.90K
61.81%
-282.90K
2023Q2
173
831.24K
82.60%
-68.86K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Kaupinen (Wesley H.)
1.61M
14.53%
--
--
Apr 14, 2025
BVF Partners L.P.
696.55K
6.3%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
714.46K
6.46%
--
--
Jun 30, 2025
Frazier Life Sciences Management, L.P.
722.40K
6.53%
+32.39K
+4.69%
Jun 30, 2025
Integrated Finance Group
559.95K
5.06%
+559.95K
--
Apr 14, 2025
The Vanguard Group, Inc.
163.81K
1.48%
+25.38K
+18.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
409.73K
3.7%
+298.98K
+269.95%
Jun 30, 2025
Woodline Partners LP
445.62K
4.03%
+251.45K
+129.50%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月2日 週二
更新時間: 12月2日 週二
機構名稱
佔比
Invesco Dorsey Wright SmallCap Momentum ETF
0.51%
ALPS Medical Breakthroughs ETF
0.37%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
iShares Russell 2000 Growth ETF
0.03%
Global X Russell 2000 ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
查看更多
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.51%
ALPS Medical Breakthroughs ETF
佔比0.37%
iShares Micro-Cap ETF
佔比0.11%
Vanguard US Momentum Factor ETF
佔比0.1%
iShares Russell 2000 Growth ETF
佔比0.03%
Global X Russell 2000 ETF
佔比0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
佔比0.02%
ProShares Hedge Replication ETF
佔比0.02%
iShares Russell 2000 ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
公告日期
類型
比率
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
Apr 18, 2024
Merger
80→1
常見問題
Palvella Therapeutics Inc的前五大股東是誰？
Palvella Therapeutics Inc的前五大股東如下：
Kaupinen (Wesley H.)持有股份：1.61M佔總股份比例：14.53%。
BVF Partners L.P.持有股份：696.55K佔總股份比例：6.30%。
Suvretta Capital Management, LLC持有股份：714.46K佔總股份比例：6.46%。
Frazier Life Sciences Management, L.P.持有股份：722.40K佔總股份比例：6.53%。
Integrated Finance Group持有股份：559.95K佔總股份比例：5.06%。
Kaupinen (Wesley H.)持有股份：1.61M佔總股份比例：14.53%。
BVF Partners L.P.持有股份：696.55K佔總股份比例：6.30%。
Suvretta Capital Management, LLC持有股份：714.46K佔總股份比例：6.46%。
Frazier Life Sciences Management, L.P.持有股份：722.40K佔總股份比例：6.53%。
Integrated Finance Group持有股份：559.95K佔總股份比例：5.06%。
Palvella Therapeutics Inc的前三大股東類型是什麼？
Palvella Therapeutics Inc 的前三大股東類型分別是：
Kaupinen (Wesley H.)
BVF Partners L.P.
Suvretta Capital Management, LLC
Kaupinen (Wesley H.)
BVF Partners L.P.
Suvretta Capital Management, LLC
有多少機構持有Palvella Therapeutics Inc(PVLA)的股份？
截至2025Q3，共有145家機構持有Palvella Therapeutics Inc的股份，合計持有的股份價值約為6.92M，占公司總股份的62.61% 。與2025Q2相比，機構持股有所增加，增幅為-9.92%。
哪個業務部門對Palvella Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Palvella Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
